Brookdale Senior Living Inc. owns, manages, and operates senior living communities in the United States.
$9.17+2.34%
报价 2026-11-13
市值
$2.19B
EV
$7.4B
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -45.3%
$8.96$16.77
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
爆发潜力
2026-11-13未命中✗ 收入线✗ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22027-12 | 1.0x | -0.16 → 0.09（扭亏） | 106.8 |
| FY+32028-12 | 1.1x | -0.16 → 0.36（扭亏） | 25.2 |
毛利率 14% · TTM 收入 $2950M · 基数 EPS -0.16（调整后）
电话会信号
辅助标签Q3 20262026-11-06
下调/撤回指引
指引 下调
信心 3
分析师 2
“We remain confident that we can drive durable mid-teens annual adjusted EBITDA growth in 2027 and beyond.”
原文引用（1）
- 下调/撤回指引：We now expect full year 2026 adjusted EBITDA of $495 million to $502 million and are lowering our RevPAR growth guidance to a range of 7.4% to 7.9%.
蓝色标签在暴涨研究中略有区分度；悬停查看口径。
研究结论
L2 2026-07-02全文 ↓尚未生成 L3 估值，没有三情景目标价。去生成估值 →
L2 报告格式无法提取要点，请看全文。
历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| BKDBrookdale Senior Living Inc. | $2.19B | +2.3% | -9.5% | 28.7% | – | 18.0x | 151.5x | |
| IBRXImmunityBio, Inc. | $6.4B | -0.8% | +77.3% | 94.6% | – | – | – | |
| COGTCogent Biosciences, Inc. | $4.97B | -2.0% | +260.0% | 0% | – | – | – | |
| ACHCAcadia Healthcare Company, Inc. | $3.51B | -0.1% | +4.9% | 19.3% | – | – | – | |
| NHCNational HealthCare Corporation | $3.26B | -1.4% | – | – | – | – | – | |
| DNLIDenali Therapeutics Inc. | $3B | -0.8% | +2004.0% | 0% | – | – | – | |
| AVAHAveanna Healthcare Holdings Inc. | $2.51B | -6.0% | +11.5% | 32.6% | 9.9x | 13.8x | 18.0x | GARP |
| RCUSArcus Biosciences, Inc. | $2.51B | -1.9% | -70.6% | 97% | – | – | – | |
| ARDTArdent Health Partners, LLC | $2.51B | +0.7% | +2.0% | 15.9% | 17.5x | 8.4x | 9.1x | |
| 同行中位数 | – | – | +11.5% | 19.3% | 13.7x | 11.1x | 13.6x |
研究全文
财务报表
| Metric | 2026-09-30 Q3 2026 | 2026-06-30 Q2 2026 | 2026-03-31 Q1 2026 | 2025-12-31 Q4 2025 | 2025-09-30 Q3 2025 | 2025-06-30 Q2 2025 | 2025-03-31 Q1 2025 | 2024-12-31 Q4 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $712.1M | $718.6M | $764.9M | $754.1M | $777.8M | $812.9M | $780.1M | $747M |
| Gross Margin | 28.7% | 28.6% | 3.3% | -1.2% | 27.4% | 26.6% | 28.9% | 26% |
| Operating Margin | 5.8% | 11.9% | 7.2% | 3.5% | -6.9% | 1.8% | 3.8% | -0.3% |
| Net Income | $-13.9M | $23.3M | $-6.9M | $-40M | $-114.7M | $-43M | $-65M | $-83.9M |
| Diluted EPS | -0.06 | 0.1 | -0.03 | -0.17 | -0.48 | -0.18 | -0.28 | -0.37 |
| Operating Cash Flow | $84.9M | $91.9M | $20.9M | $34.5M | $76.5M | $83.6M | $23.4M | $45.2M |
研究材料
Filing 摘要